Amplia Therapeutics Reports Positive Cancer Trial Data

Amplia Therapeutics has released updated data from its ACCENT pancreatic cancer trial, reporting four additional complete responses. The analysis also indicates improved overall survival rates among participants. These encouraging results suggest the potential efficacy of the company's treatment in a challenging cancer indication. Amplia Therapeutics is advancing its research, aiming to provide new therapeutic options for patients battling pancreatic cancer.